Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus - 1 Sept 2017

Hillman L, Yadlapati R, Thuluvath A J, Berendsen M A, Pandolfino J E

Abstract excerpt

Up to 40% of patients report persistent gastroesophageal reflux disease (GERD) symptoms despite proton pump inhibitor (PPI) therapy. This review outlines the evidence for medical therapy for PPI nonresponsive GERD. A literature search for GERD therapies from 2005 to 2015 in PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews identified 2928 unique...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastroesophageal Reflux

Share to Gastrointestinal Agents

Share to Genotype

Share to Morpholines

Share to Proton Pump Inhibitors

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 28859358
DOI: 10.1093/dote/dox055
PMCID: PMC5788178

Genes

CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.PMID 28859358Read ↗

Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.Semantic proximity Read ↗

Optimal management of severe symptomatic gastroesophageal reflux disease.Semantic proximity Read ↗

Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.Semantic proximity Read ↗

The Effects of Advanced Diagnostic Methods and Disease Phenotypes on the Response to PPI in Patients with Gastroesophageal Reflux Disease.Semantic proximity Read ↗

Genetic variations in medical versus surgical patients with GERD: beyond PPIs and fundoplications.Semantic proximity Read ↗

Pharmacologic Therapies in Gastrointestinal Diseases.Semantic proximity Read ↗

[Underlying Mechanisms and Management of Refractory Gastroesophageal Reflux Disease].Semantic proximity Read ↗

Gastroesophageal Reflux Disease.Semantic proximity Read ↗

Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Semantic proximity Read ↗

New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.Semantic proximity Read ↗

Proton-Pump Inhibitors in Eosinophilic Esophagitis: A Review Focused on the Role of PharmacogeneticsSemantic proximity Read ↗

Proton Pump Inhibitors in Pediatric Gastroesophageal Reflux Disease: A Systematic Review of Randomised Controlled TrialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.